BerGenBio Valuation

Is 0RU5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RU5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RU5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RU5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RU5?

Key metric: As 0RU5 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0RU5. This is calculated by dividing 0RU5's market cap by their current book value.
What is 0RU5's PB Ratio?
PB Ratio	2.3x
Book	NOK 153.38m
Market Cap	NOK 355.58m

0RU5 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	346.9x
Enterprise Value/EBITDA	-1.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does 0RU5's PB Ratio compare to its peers?

The above table shows the PB ratio for 0RU5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	4.5x
HEMO Hemogenyx Pharmaceuticals	4.7x	n/a	UK£14.3m
OPTI OptiBiotix Health	2.5x	n/a	UK£18.6m
ETX e-therapeutics	1.9x	n/a	UK£52.6m
PBX ProBiotix Health	9x	n/a	UK£11.5m
0RU5 BerGenBio	2.3x	-23.5%	NOK 355.6m

Price-To-Book vs Peers: 0RU5 is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (4.5x).

Price to Book Ratio vs Industry

How does 0RU5's PB Ratio compare vs other companies in the GB Biotechs Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
DEST Destiny Pharma	0.3x	-15.5%	US$5.85m
BDRX Biodexa Pharmaceuticals	0.5x	n/a	US$4.42m
LLAI LungLife AI	0.4x	101.0%	US$2.86m
VAL ValiRx	0.2x	n/a	US$1.15m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: 0RU5 is good value based on its Price-To-Book Ratio (2.3x) compared to the UK Biotechs industry average (3.2x).

Price to Book Ratio vs Fair Ratio

What is 0RU5's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RU5 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0RU5's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RU5 forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	NOK 9.67	NOK 20.00 +106.9%	68.2%	NOK 38.00	NOK 5.00	n/a	3
Dec ’25	NOK 11.50	NOK 20.00 +73.9%	68.2%	NOK 38.00	NOK 5.00	n/a	3
Nov ’25	NOK 8.55	NOK 20.00 +133.9%	68.2%	NOK 38.00	NOK 5.00	n/a	3
Oct ’25	NOK 10.28	NOK 20.00 +94.6%	68.2%	NOK 38.00	NOK 5.00	n/a	3
Sep ’25	n/a	NOK 20.00 0%	68.2%	NOK 38.00	NOK 5.00	n/a	3
Aug ’25	NOK 13.16	NOK 30.67 +133.0%	92.1%	NOK 70.00	NOK 5.00	n/a	3
Jul ’25	NOK 11.87	NOK 33.33 +180.8%	81.5%	NOK 70.00	NOK 5.00	n/a	3
Jun ’25	NOK 14.28	NOK 33.33 +133.4%	81.5%	NOK 70.00	NOK 5.00	n/a	3
May ’25	n/a	NOK 76.67 0%	114.2%	NOK 200.00	NOK 5.00	n/a	3
Apr ’25	NOK 19.05	NOK 76.67 +302.5%	114.2%	NOK 200.00	NOK 5.00	n/a	3
Mar ’25	NOK 19.52	NOK 76.67 +292.7%	114.2%	NOK 200.00	NOK 5.00	n/a	3
Feb ’25	NOK 26.80	NOK 76.67 +186.1%	114.2%	NOK 200.00	NOK 5.00	n/a	3
Jan ’25	NOK 27.85	NOK 76.67 +175.3%	114.2%	NOK 200.00	NOK 5.00	NOK 8.13	3
Dec ’24	NOK 17.90	NOK 76.67 +328.4%	114.2%	NOK 200.00	NOK 5.00	NOK 11.50	3
Nov ’24	NOK 19.80	NOK 568.33 +2,770.4%	116.8%	NOK 1,500.00	NOK 5.00	NOK 8.55	3
Oct ’24	NOK 10.68	NOK 568.33 +5,221.5%	116.8%	NOK 1,500.00	NOK 5.00	NOK 10.28	3
Sep ’24	NOK 11.32	NOK 568.33 +4,920.6%	116.8%	NOK 1,500.00	NOK 5.00	n/a	3
Aug ’24	NOK 10.04	NOK 1,501.67 +14,856.8%	81.4%	NOK 3,000.00	NOK 5.00	NOK 13.16	3
Jul ’24	NOK 9.10	NOK 1,533.33 +16,749.8%	77.2%	NOK 3,000.00	NOK 100.00	NOK 11.87	3
Jun ’24	NOK 38.43	NOK 1,533.33 +3,889.7%	77.2%	NOK 3,000.00	NOK 100.00	NOK 14.28	3
May ’24	NOK 184.80	NOK 1,533.33 +729.7%	77.2%	NOK 3,000.00	NOK 100.00	n/a	3
Apr ’24	n/a	NOK 1,800.00 0%	49.1%	NOK 3,000.00	NOK 900.00	NOK 19.05	3
Mar ’24	n/a	NOK 1,800.00 0%	49.1%	NOK 3,000.00	NOK 900.00	NOK 19.52	3
Feb ’24	NOK 677.50	NOK 1,800.00 +165.7%	49.1%	NOK 3,000.00	NOK 900.00	NOK 26.80	3
Jan ’24	n/a	NOK 1,800.00 0%	49.1%	NOK 3,000.00	NOK 900.00	NOK 27.85	3

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 17:45
End of Day Share Price	2025/01/02 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BerGenBio ASA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ulrik Trattner	Carnegie Investment Bank AB
Patrik Ling	DNB Markets
Geir Holom	DNB Markets